IN THE NEWS
Scrip Pharma Intelligence
January 4, 2023Scrip Asks…What Does 2023 Hold For Biopharma? Part 1: The Funding Environment
“I expect that we will see more flat or down rounds with private life science companies in early 2023 as companies get to the end of their cash runway and need additional funding to take them to data catalysts. Many of these rounds will likely be insider rounds with existing investors. Once we see the IPO market re-open, which I expect will happen in H2 2023, then we will likely see more money start to flow into both public and private life science companies and we will start to see valuations increase,” said James Mackay, CEO of Aristea Therapeutics, Inc. read more →
PharmaLive
December 13, 2022Pharma people on the move: Fall 2022 roundup
San Diego-based Aristea Therapeutics has appointed three experienced drug development experts to key positions. Himanshu Patel, D.O., is executive medical director; Jennifer Barnes, Ph.D., is senior director, clinical science; and Walter Frank Eng, Pharm.D., is associate director, clinical science. read more →
PharmaVoice
December 12, 2022The 2023 PharmaVoice Year in Preview
A look at how industry leaders are navigating the key issues of 2023. read more →
NPR BioTech Nation with Dr. Moira Gunn
December 4, 202222-47 Dr. James Mackey, President & CEO, Aristea Therapeutics
Too much of a good thing spells trouble - in this case, that would be neutrophils – the white blood cells that act as our immune system’s first line of defense. It's called PPP, or Palmoplantar Pustulosis. Dr. James Mackey is the President & CEO of Aristea Therapeutics. read more →
Life Science Leader
December 2, 20222023 Finance And Funding Outlook: Additional Insights Part 1
Biopharma’s have been in a fundraising recession for over a year which has forced many to already begin making tough choices... read more →
BioSpace (Alex Keown)
November 4, 2022Movers & Shakers
San Diego-based Aristea bolstered its clinical operations team with three appointments. Himanshu Patel was named executive medical director; Jennifer Barnes was named senior director of clinical science; and Walter Frank Eng was named associate director of clinical science. read more →
Fierce Biotech (Max Bayer, Gabrielle Masson)
November 4, 2022Chutes & Ladders
Immunology company Aristea Therapeutics has appointed three new leaders in positions that will guide drug development. read more →
BioWorld
November 2, 2022Appointments and advancements for Nov. 2, 2022
New hires and promotions in the biopharma industry, including: Actinium, Ambrx, Anebulo, Aristea... read more →
Life Science Leader
November 1, 2022Aristea CEO Talks Rare Disease Endpoints And Parallel Fundraising
San Diego-based Aristea Therapeutics, spun out of AstraZeneca in 2018 and led by founder, president, and CEO James Mackay, is less than one year away from a clinical trial read-out that could change the company’s trajectory, as well as advance a new drug candidate into late-stage trials for a rare disease with no approved products on the market. read more →
Endpoints News
August 26, 2022No Myth: CEO of ADC upstart calls it quits; Bristol Myers vet Jon Wigginton scales new heights at Bright Peak
Now partnering with Pfizer on an old AstraZeneca drug named RIST4721 after initially striking the deal with Arena last summer, Aristea Therapeutics has added Poseida Therapeutics CEO Mark Gergen and Novo Ventures partner Daniel O’Connell to the board of read more →
BioWorld
August 24, 2022Appointments and advancements for Aug. 24, 2022
Aristea Therapeutics Inc., of San Diego, added Mark Gergen and Daniel O'Connell to its board. Michael Vincent joins as a board observer. read more →
Empowered Patient Podcast
August 2, 2022Treating Inflammatory Diseases by Blocking Neutrophils Moving from Bone Marrow
James Mackay is the Founder, President, and CEO of Aristea Therapeutics, a San Diego-based company that is applying its insights on neutrophils to develop a treatment for a rare inflammatory skin condition known as palmoplantar pustulosis, PPP. Most of the people who get this disease are postmenopausal females, and 90%+ of the patients either are current cigarette smokers or have a history of cigarette smoking. read more →
Tech Nation Radio Podcast
July 15, 2022Tech Visionary – No Tech
Dr. James Mackey, the President & CEO, Aristea Therapeutics, tells about a painful disease which affects the palms of hand and soles of feet in post-menopausal women - Palmoplantar pustulosis or PPP - and how it may relate to other diseases. read more →
Clinical Trials Arena
July 14, 2022Aristea contemplates Phase III design for rare skin disease drug
As Aristea develops a palmoplantar pustulosis treatment, US and European regulators indicate different primary endpoint preferences. read more →
Pharmaceutical Executive
July 8, 2022A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs
COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a key strategic cog. read more →
BioTuesdays
July 5, 2022Aristea Therapeutics in four clinical trials in rare inflammatory diseases
Closely-held Aristea Therapeutics is pursuing four rare inflammatory diseases with its oral, once-daily, small molecule drug candidate, RIST4721: palmoplantar pustulosis, familial Mediterranean fever, Behcet's disease and hidradenitis suppurativa. read more →
Rheumatology Network
June 10, 2022Familial Mediterranean Fever: Minimizing Inflammation and Preventing Flares
Nihar Bhakta, MD, explains Familial Mediterranean Fever, a rare rheumatic disease, and how Aristea Therapeutics is working to treat patients suffering from this condition. read more →
Two Disabled Dudes Podcast
May 15, 2022Doing the Right Thing with James Mackay, CEO Aristea Tx
James Mackay, PhD, Founder, President and Chief Executive Officer of Aristea Therapeutics, has over 25 years of development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. James joins The Dudes to discuss his experience and how he is contributing to the biotech leadership community. read more →
BioSpace
April 4, 2022Clinical Catch-Up: Adagio to Seek COVID-19 EUA, CytoDyn’s Bad Week
It was a particularly busy week for clinical trial announcements. read more →
RAREcast
March 18, 2022Targeting Rare, Immunologic Disorders
Aristea Therapeutics was spun out of AstraZeneca to develop medicines for rare, immunologic disorders. Its lead program in development is an experimental therapy for a rare skin condition that causes repeated outbreaks of painful pustules on the hands and feet and is being looked at for other neutrophil-mediated diseases. We spoke to James Mackay, president and CEO of Aristea, about the decision to form the company, its lead therapy in development, and its collaboration and development deal with Arena Pharmaceuticals that gives its partner an option to acquire it outright. read more →
BioSpace
March 9, 2022COVID-19 Changed the Biopharma Industry – and There’s No Going Back
As the COVID-19 pandemic approaches its second anniversary in North America, the medical industry looks much different than it did just two years ago. Health and safety protocols have changed drastically, economies are still shifting and political tensions have heightened as a result of restrictions put in place to manage the virus. read more →
Finding Genius Podcast
March 6, 2022Drug Development for Inflammatory Disease and the Research Surrounding Gout Therapeutics with Nihar Bhakta
Why has Gout been an incredibly challenging condition for many individuals to treat? Even though treatments have been developed and used, Gout flares can remain, being an incredibly painful and diminishing quality of life. Listen to learn. read more →
CFO Dive
February 23, 2022First-time biotech CFO strategizes for future with or without big pharma
Since taking over as finance chief of the small biotech company Aristea Therapeutics Inc. last year, first-time CFO Justin Thacker has stretched into his new strategic responsibilities to help prepare the company for a range of scenarios, including a public offering. read more →
Biotech 2050 Podcast
February 16, 2022From pharma to founding a biotech, James Mackay, Founder, President & CEO, Aristea Therapeutics
James Mackay, PhD, Founder, President and Chief Executive Officer, has over 25 years of development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. read more →
Finding Genius Podcast
February 10, 2022Palmoplantar Pustulosis Symptoms and the Causes and Treatments for Inflammatory Skin Diseases with James Mackay
What makes palmoplantar pustulosis symptoms so difficult to treat? Based on its unique makeup, relief can be challenging to find. Listen to learn. read more →
BioSpace
January 24, 2022Aristea is Rehoming Proven Molecules for Rare Inflammatory Diseases
Aristea Therapeutics is on a rescue mission. The San Diego-based immunology company is using its considerable expertise and experience to locate and develop molecules where the mechanism of action has either been proven or makes sense. read more →
Clinical OMICs
December 14, 2021Pfizer Acquires Arena for $6.7B To Improve Immuno-Inflammatory Offering
Pfizer will acquire Arena Pharmaceuticals in a deal worth $6.7 billion to expand its pipeline of immuno-inflammatory disease drugs in development. read more →
Genetic Engineering & Biotechnology News
December 13, 2021Pfizer to Acquire Arena for $6.7B, Expanding Immuno-Inflammatory Pipeline
Pfizer has agreed to acquire Arena Pharmaceuticals for approximately $6.7 billion, the companies said today, in a deal designed to expand the buyer’s immuno-inflammatory disease pipeline, led by Arena’s Phase II/II lead candidate etrasimod. read more →
Rare Disease, Cell & Gene Therapy Monthly RoundUp
November 30, 2021Special episode featuring James Mackay – November 2021
James provides insights on his experience with setting up a biotech and challenges associated, industry climate on spin off opportunities, Aristea’s pipeline, collaborations and US PRMA reforms. read more →
HealthBiz
October 6, 2021Interview with Aristea Therapeutics CEO James Mackay
Aristea is developing drugs for inflammatory diseases, starting with palmoplantar pustulosis. James shares his journey from small town Scotland to big pharma and San Diego. read more →
BioSpace
September 20, 2021It’s a New Hybrid World for Biopharma
The hybrid workplace is here, and by most accounts, biopharmas - medium and small - appear to be embracing it. read more →
Outsourced Pharma
September 8, 2021Do You Understand The Motives of Your Advisors?
Over two previous editorials, James Mackay, Aristea Therapeutics CEO, and experienced independent board member to emerging biopharma organizations, has explained his role as an advisor to CEOs and member of governing boards, most particularly as it relates to the outsourcing function. read more →
Outsourced Pharma
September 1, 2021How Involved Should Biopharma CEOs Be In Outsourcing Activities?
James Mackay, CEO of Aristea Therapeutics, and independent board member to emerging biopharma, says when he's advising new CEOs, he answers by first informing them at some point along the way... read more →
Endpoints News
August 27, 2021AstraZeneca promotes oncology exec to CMO; Pfizer replaces retiring chief dealmaker as war chest expands
San Diego-based Aristea Therapeutics has tapped Justin Thacker as CFO. read more →
BioSpace
August 27, 2021BioSpace Movers & Shakers, Aug. 27
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. read more →
Fierce Biotech
August 27, 2021Chutes & Ladders—Pfizer taps McKinsey U.S. managing partner as new M&A leader
Justin Thacker joined immunology biotech Aristea Therapeutics as chief financial officer. read more →
BioWorld
August 24, 2021Appointments and advancements for Aug. 23, 2021
New hires and promotions in the biopharma industry, including: Aristea... read more →
Genetic Engineering & Biotechnology News
August 16, 2021Wider Arena: Aristea Pursues Excellence with $123M in Investment
Collaboration with San Diego neighbor Arena Pharma, and a $63-million Series B propel development of drug cast off by AstraZeneca, says CEO James Mackay read more →
Outsourced Pharma
August 11, 2021An Independent Board Member Advises Emerging Biopharma On Outsourcing
What exactly is an independent board member? read more →
Life Science Leader
July 30, 2021Back to the Office
Since lockdowns that began mid-Mar. 2020, remote work became the new norm for many, along with a new perspective. From the boardroom down to entry-level positions, knowledge workers suddenly saw their work and personal lives in a completely new light. read more →
San Diego Metro
July 29, 2021Daily Business Report: Thursday, July 29, 2021
Aristea Therapeutics, a San Diego clinical-stage immunology-focused drug development company developing novel therapies to treat serious inflammatory orphan diseases, announced the closing of a $63 million Series B financing. read more →
Endpoints News
July 28, 2021AstraZeneca castoff draws $128M wager on CXCR2 antagonist as Arena lines up a buyout option
Back in 2018, James Mackay — then leading an inflammatory disease group at AstraZeneca after leading the pharma giant’s acquisition of Ardea — took interest in a drug that’d been relegated to the shelves four years earlier. read more →
Benzinga
July 28, 2021Arena Pharma In-Licenses Aristea’s CXCR2 Antagonist For Immune-Mediated Inflammatory Disease
Arena Pharmaceuticals Inc and Aristea Therapeutics Inc have collaborated to develop RIST4721 for palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases. read more →
The Pharma Letter
July 28, 2021Arena inks deal with Aristea for RIST4721 and acquisition option
US companies Arena Pharmaceuticals and Aristea Therapeutics have entered into a strategic collaboration. read more →
Fierce Biotech
July 28, 2021Arena taps Aristea in $70M inflammation deal, secures buyout option
Arena Pharmaceuticals is ponying up $60 million upfront and investing $10 million in Aristea Therapeutics to collaborate on the latter’s inflammatory disease program and snag the option to acquire its partner. read more →
BioWorld
July 28, 2021Financings for July 28, 2021
Biopharmas raising money in public or private financings, including: Aristea read more →
BioWorld
July 28, 2021Other news to note for July 28, 2021
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief. read more →
BioSpace
July 27, 2021Money on the Move: July 21 – 27, 2021
A quick overview of life science companies scooping up some summer spending money this week including: Aristea. read more →
Seeking Alpha
July 27, 2021Arena Pharmaceuticals and Aristea ink RIST4721 collaboration agreement
Arena Pharmaceuticals (NASDAQ:ARNA) and Aristea Therapeutics announce a strategic collaboration to advance the clinical development of RIST4721, an oral CXCR2 antagonist being developed by Aristea for the treatment of palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases. read more →
BioCentury
July 27, 2021Aristea plots path forward in rare skin disease with $63M series B, Arena deal
Arena obtains option to acquire well-funded AZ spinout after palmoplantar pustulosis readout. read more →
BioPharma Dive
July 27, 2021An AstraZeneca spinout scores a buyout option from Arena
Arena Pharmaceuticals has paid $60 million for an option to acquire Aristea Therapeutics, a private biotech founded in 2018 to develop an experimental inflammatory drug discovered by AstraZeneca. read more →